Daniel J Zabransky

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6312013/daniel-j-zabransky-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19	517	11	2 O
papers	citations	h-index	g-index
20	650 ext. citations	10.3	2.49
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
19	Shared genetic and epigenetic changes link aging and cancer Trends in Cell Biology, 2022,	18.3	3
18	PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model <i>Oncotarget</i> , 2022 , 13, 373-386	3.3	
17	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. <i>OncoImmunology</i> , 2021 , 10, 2001159	7.2	1
16	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. Journal of Clinical Investigation, 2021, 131,	15.9	5
15	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4708-4723	15.9	21
14	The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 401-412	4.4	2
13	PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 451-464	4.4	12
12	Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. <i>Clinical Cancer Research</i> , 2017 , 23, 4875-4884	12.9	25
11	Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR. <i>Clinical Chemistry</i> , 2017 , 63, 1370-1376	5.5	3
10	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 379-386	12.9	36
9	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 993-9	12.9	129
8	Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. <i>Oncotarget</i> , 2016 , 7, 6281-93	3.3	49
7	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. <i>Clinical Biochemistry</i> , 2015 , 48, 993-8	3.5	77
6	HER2 missense mutations have distinct effects on oncogenic signaling and migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E6205-14	11.5	51
5	NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11583-8	11.5	17
4	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. <i>Oncotarget</i> , 2015 , 6, 25240-51	3.3	7
3	TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. <i>Oncotarget</i> , 2015 , 6, 44927-40	3.3	24

LIST OF PUBLICATIONS

Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies 2 2.2 7 for breast cancer. Journal of Clinical Oncology, 2014, 32, 1084-6

MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proceedings of the National Academy of Sciences of the United States of America, **2014**, 111, 17606-11

11.5 46